List of Excipients in Branded Drug MONTELUKAST

Generic Drugs Containing MONTELUKAST

Company	Ingredient	NDC	Excipient
West ward Pharmaceutical Corp	montelukast	0143-9649	CARNAUBA WAX
West ward Pharmaceutical Corp	montelukast	0143-9649	CELLULOSE, MICROCRYSTALLINE
West ward Pharmaceutical Corp	montelukast	0143-9649	CROSCARMELLOSE SODIUM
West ward Pharmaceutical Corp	montelukast	0143-9649	FERRIC OXIDE RED
West ward Pharmaceutical Corp	montelukast	0143-9649	FERRIC OXIDE YELLOW
West ward Pharmaceutical Corp	montelukast	0143-9649	HYDROXYPROPYL CELLULOSE

What are the Most Frequently-Used Excipients in MONTELUKAST?

# Of NDCs	Excipient
1	ASPARTAME
17	CARNAUBA WAX
27	CELLULOSE, MICROCRYSTALLINE
1	CHERRY
27	CROSCARMELLOSE SODIUM
7	EDETATE DISODIUM

Last updated: August 10, 2026

Executive summary: Montelukast is a mature, off-patent leukotriene receptor antagonist with broad generic availability and limited opportunity for conventional API or tablet differentiation. The strongest commercial openings are excipient-led: pediatric granules, sugar-free and aspartame-free chewables, low-sodium formulations, orally disintegrating dosage forms, taste-masked products, and region-specific presentations for asthma and allergic rhinitis. FDA’s boxed warning for serious neuropsychiatric events constrains promotion and makes formulation changes commercially valuable only when they improve adherence, dosing flexibility, or access rather than expand the indication [1].

Montelukast Excipient Strategy and Commercial Opportunities

Montelukast sodium has a commoditized active ingredient but differentiated formulation opportunities. The most defensible strategy is to target usability, pediatric administration, excipient tolerability, and manufacturing efficiency.

Montelukast is marketed primarily as 10 mg film-coated tablets for adults and adolescents, 5 mg and 4 mg chewable tablets for pediatric patients, and 4 mg oral granules for younger children. Generic products are approved through abbreviated new drug applications, while alternative dosage forms may use the 505(b)(2) pathway if they rely on clinical or bioavailability data beyond a standard generic approach [2].

The commercial value of a new montelukast product will depend less on the molecule and more on five factors:

1. Pediatric acceptability and dose administration.
2. Removal of high-scrutiny excipients such as aspartame, lactose, or artificial colors.
3. Stable, low-cost manufacturing of low-dose units.
4. Packaging that protects the formulation from moisture and light.
5. A regulatory position that avoids creating new neuropsychiatric-risk concerns.

What formulations are currently protected or commercially established for montelukast?

Montelukast products are established in three principal dosage forms.

Dosage form	Common strengths	Primary patient segment	Core formulation issue
Film-coated tablet	10 mg	Adults and adolescents	Swallowability, content uniformity, coating performance
Chewable tablet	4 mg, 5 mg	Children	Taste, mouthfeel, sweetener selection, tablet robustness
Oral granules	4 mg	Young children	Dose flexibility, sachet stability, administration with food or soft foods

The original Singulair formulations used conventional pharmaceutical excipients. The 10 mg tablet label identifies microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, hydroxypropyl cellulose, magnesium stearate, titanium dioxide, ferric oxide, and carnauba wax among the inactive ingredients. The chewable tablets used mannitol, microcrystalline cellulose, hydroxypropyl cellulose, croscarmellose sodium, aspartame, flavoring, magnesium stearate, and colorants. The granule formulation used mannitol, hydroxypropyl cellulose, and magnesium stearate [3].

These compositions establish technical precedent but do not prevent alternative excipient systems. Generic manufacturers can use different excipients if they meet quality, bioequivalence, dissolution, stability, and labeling requirements.

Which excipients are most important in montelukast formulations?

Fillers and diluents

Mannitol is commercially attractive for chewable tablets and granules because it provides a cooling mouthfeel and low hygroscopicity relative to several other polyols. It can support sugar-free positioning and is widely accepted in pediatric products.

Microcrystalline cellulose is useful in compressed tablets because it supports compactibility and tablet strength. It is less attractive as the sole diluent in a chewable product where a fibrous mouthfeel can impair palatability.

Lactose is a cost-effective filler for conventional tablets, but lactose-free positioning may have value in selected markets. Lactose intolerance is not equivalent to milk-protein allergy, so marketing claims must be carefully controlled.

Binders and disintegrants

Hydroxypropyl cellulose can function as a binder and improve granule structure. Croscarmellose sodium supports rapid tablet breakup, but excessive levels can impair tablet mechanical strength or create processing variability.

Low-dose montelukast products require tight content-uniformity control. The formulation must distribute a small quantity of active ingredient consistently across a relatively large mass of excipients. Wet granulation, dry granulation, or direct compression may each be viable, but the choice affects blend uniformity, segregation, dissolution, and scale-up risk.

Lubricants and surfactants

Magnesium stearate is a standard lubricant but can slow wetting or dissolution when overmixed. Lubrication time should be treated as a critical process parameter, particularly for chewable tablets and orally disintegrating systems.

Sodium lauryl sulfate or another wetting agent may be considered where montelukast’s low dose, hydrophobic behavior, or dissolution profile creates a manufacturing problem. Surfactant use adds sensory and tolerability considerations, especially in pediatric formulations.

Sweeteners and flavors

Aspartame provides strong sweetness at low concentration but contains phenylalanine and requires a phenylketonuria warning. An aspartame-free product can address institutional procurement, caregiver preference, and patients who need to avoid phenylalanine exposure.

Sucralose, acesulfame potassium, steviol glycosides, and polyols can support alternative sweetener systems. Each creates different risks:

• Polyols may produce gastrointestinal effects at higher exposure.
• Steviol glycosides can create bitterness or lingering taste.
• Sucralose and acesulfame potassium may require flavor balancing.
• Flavor systems can vary by geography and may complicate global registration.

For montelukast, taste masking is a central development issue because the active ingredient can produce bitterness. A simple sweetener substitution may not be sufficient. Polymer coating, ion-exchange complexation, lipid barriers, or multiparticulate encapsulation may produce stronger sensory performance but increase cost and regulatory complexity.

Colors and coating materials

A color-free formulation can reduce concerns about artificial dyes and simplify procurement in markets with restrictive color preferences. Titanium dioxide restrictions in some jurisdictions also support development of non-titanium dioxide coating systems.

Film coatings based on hypromellose, polyvinyl alcohol, polyethylene glycol, talc, and iron oxides can be optimized for appearance, swallowability, and moisture protection. Coating is unlikely to create a strong standalone patent position unless it contributes to a measurable performance advantage.

What excipient strategies create the strongest commercial opportunities?

Aspartame-free chewable tablets

An aspartame-free 4 mg or 5 mg chewable tablet is one of the clearest low-complexity opportunities. The product can retain mannitol-based sensory properties while replacing aspartame with a combination of sucralose, acesulfame potassium, stevia, or a polyol system.

The key development targets are:

• Bitterness suppression.
• Acceptable aftertaste.
• Adequate hardness and friability.
• Fast disintegration after chewing.
• Stability under high humidity.
• Clear labeling for sweetener composition.

The commercial opportunity is strongest where pediatric prescribers, caregivers, or hospital formularies prefer phenylalanine-free products.

Sugar-free and dye-free pediatric products

Many montelukast chewables are already sugar-free because they use mannitol rather than sucrose. A more differentiated proposition would combine sugar-free, aspartame-free, and artificial-color-free attributes in one product.

This approach can support premium positioning, but the claims are not intrinsically exclusive. A competitor can replicate the same excipient concept unless the formulation has a meaningful patentable feature, such as a defined taste-masking system, improved stability, or a specific dissolution profile.

Oral granules with flexible administration

The 4 mg granule format is commercially relevant for children who cannot chew or swallow tablets. The granules can be administered directly or mixed with a limited quantity of soft food, depending on the product label [3].

Potential improvements include:

• Single-dose sachets with better moisture barriers.
• Smaller granule size for improved mouthfeel.
• Reduced bitterness after dispersion.
• Unit-dose packaging for adherence.
• Formulations that remain stable after short-term mixing with approved foods.
• Easier opening systems for caregivers.

The main technical risk is that a change in particle size, coating, or food interaction can alter dissolution and exposure. Any claim involving administration with food requires direct support from pharmacokinetic and stability data.

Orally disintegrating tablets

An orally disintegrating tablet could address adolescents and adults with swallowing difficulty, as well as patients seeking administration without water. Mannitol, crospovidone, low-substituted hydroxypropyl cellulose, and specialized compression aids are relevant excipient choices.

The formulation must balance rapid disintegration with adequate mechanical strength. Montelukast’s taste makes direct-release ODT development more difficult than conventional tablets. A coated granule-in-tablet or taste-masked ODT may be more commercially credible than an uncoated fast-dissolving tablet.

Liquid and reconstitutable products

A liquid formulation could serve patients who cannot use tablets or granules. However, montelukast’s physicochemical properties, taste, preservative requirements, and dose-volume burden make liquids less attractive than granules.

Commercial development would need to resolve:

• Solubility or suspension uniformity.
• Sedimentation and redispersibility.
• Microbial preservation.
• Dose accuracy.
• Flavor stability.
• Container compatibility.
• In-use stability after opening.

A suspension may be more practical than a true solution, but it would create additional quality-control requirements.

When did montelukast lose exclusivity?

Montelukast’s principal U.S. composition-of-matter and original-product exclusivity expired years ago. Merck’s Singulair patent estate no longer provides the basis for a current branded monopoly in the United States. The product therefore has extensive generic competition, including 10 mg tablets, chewable tablets, and granule presentations.

The key U.S. milestones were:

Milestone	Commercial significance
FDA approval of Singulair	Established the reference product and dosage-form platform
Expiration of primary patent protection	Opened the market to generic entry
Expiration of pediatric exclusivity	Removed the principal extension associated with pediatric studies
Generic approvals	Created price competition across tablets, chewables, and granules
2020 FDA boxed warning	Changed promotional and risk-management conditions

The original product’s commercial protection should be distinguished from later formulation patents. A narrowly drafted formulation patent may remain relevant in some jurisdictions, but it does not restore exclusivity for the active ingredient as a whole.

What is the Orange Book status of montelukast?

Montelukast is an FDA-approved small molecule, not a biologic. Its products are generally subject to the ANDA pathway, and the Orange Book framework is relevant to listed patents, therapeutic equivalence, and Paragraph IV certifications [2,4].

For a generic applicant, the principal regulatory routes are:

• Paragraph I certification if no relevant patent is listed.
• Paragraph II certification if a listed patent has expired.
• Paragraph III certification accepting delayed approval until patent expiry.
• Paragraph IV certification asserting that a listed patent is invalid, unenforceable, or not infringed.

Because the core montelukast exclusivity period has ended, a current Paragraph IV strategy would normally target a later-listed formulation, method-of-use, or product-specific patent rather than the original active-ingredient patent.

Which companies are challenging montelukast exclusivity?

Generic competition has historically included major and regional manufacturers such as Teva, Sandoz, Apotex, Mylan, Dr. Reddy’s Laboratories, Lupin, Zydus, and other ANDA sponsors, depending on market and dosage form.

The competitive issue is no longer whether generic montelukast can enter. It is whether a manufacturer can secure durable share through:

• Lower cost of goods.
• Reliable pediatric supply.
• Better sensory performance.
• Broader excipient acceptability.
• Private-label or contract-manufacturing relationships.
• Geographic registrations.
• Hospital and government tenders.

The market is fragmented enough that a differentiated excipient profile can support modest price resilience, but it is unlikely to support branded-drug pricing without a clear clinical or adherence benefit.

What patent opportunities exist for montelukast excipients and formulations?

The strongest potential patent claims would focus on a defined technical result rather than a generic list of excipients.

Potential claim areas include:

Taste-masking systems

A patent may claim a specific coated-particle architecture, polymer combination, coating weight gain, or dissolution behavior that reduces bitterness without delaying bioavailability.

Moisture-stable granules

A formulation may support claims covering low water activity, a defined moisture-barrier film, or improved stability under accelerated conditions.

Low-dose content uniformity

Process patents may address blending order, carrier particle size, granulation conditions, or segregation control. These patents can be valuable operationally but may be difficult to enforce against a competitor using a different process.

Excipient-restricted formulations

Claims directed to aspartame-free, lactose-free, dye-free, or sodium-reduced formulations may have commercial utility. Their patent strength is usually limited unless the excipient restriction produces an unexpected stability, sensory, or pharmacokinetic result.

Multiparticulate dosage forms

Coated pellets, granules, minitablets, and sachet systems can support formulation claims. Their value is highest when they materially improve administration or taste while maintaining bioequivalence.

A patent that merely substitutes one conventional filler or sweetener for another is vulnerable to obviousness challenges. Stronger protection requires comparative data against the reference product or conventional alternatives.

What FDA regulatory issues affect montelukast commercialization?

FDA added a boxed warning in 2020 concerning serious neuropsychiatric events, including suicidal thoughts or actions, and advised reserving montelukast for allergic rhinitis patients who do not respond to or cannot tolerate alternative therapies [1].

This warning affects formulation strategy in three ways:

1. It limits the value of consumer-facing positioning based solely on convenience.
2. It increases the importance of accurate labeling and caregiver instructions.
3. It reduces the commercial value of a new dosage form unless the product improves adherence or access without implying a safer neuropsychiatric profile.

A new excipient does not eliminate the active ingredient’s boxed-warning risk. Any marketing claim suggesting improved psychiatric safety would require substantial clinical evidence and could create regulatory exposure.

Montelukast has no biosimilar pathway because it is a chemically synthesized small molecule. The relevant competitors are generics, authorized generics, branded-generic products, and potentially 505(b)(2) reformulations.

How strong is the montelukast patent estate?

The patent estate is weak for the active ingredient and mature dosage forms but potentially moderate for narrowly defined delivery technologies.

Asset type	Current strategic strength
Montelukast composition of matter	Very low in the U.S.; expired core exclusivity
Conventional 10 mg tablet	Low
Standard 4 mg or 5 mg chewable	Low
Taste-masked pediatric formulation	Moderate if supported by comparative data
Novel ODT or multiparticulate system	Moderate
Manufacturing process	Moderate operational value, variable enforceability
Method of use	Limited by established indications and boxed warning
New fixed-dose combination	Potentially higher, but requires clinical and regulatory investment

Geographic coverage matters. Core U.S. rights are not a reliable source of protection, while selected formulation patents may still have commercial relevance in countries with different filing dates, patent-term rules, or local enforcement. A country-by-country freedom-to-operate review remains essential for export products.

What generic launch risks exist for montelukast?

Generic launch risk is concentrated in execution rather than patent blockage.

Key risks include:

• Failure to match dissolution across strengths.
• Poor taste acceptance in pediatric studies or market testing.
• Excipient incompatibility with montelukast sodium.
• Moisture-driven degradation or physical instability.
• Inadequate sachet barrier performance.
• Nitrosamine or elemental-impurity concerns arising from excipient and packaging supply chains.
• Inconsistent low-dose blend uniformity.
• Supply disruption for specialized flavors, coatings, or sweeteners.
• Labeling errors related to the boxed warning.
• Price erosion from multiple interchangeable products.

Manufacturers should prioritize excipients with multiple qualified suppliers. A formulation dependent on a single specialty flavor, coating polymer, or high-purity sweetener creates avoidable supply risk.

How does montelukast compare with competing asthma and allergy products?

Montelukast competes with inhaled corticosteroids, inhaled corticosteroid/long-acting bronchodilator combinations, antihistamines, and other leukotriene-pathway therapies.

Its excipient opportunity differs from inhaled products. Montelukast does not require device-engineered pulmonary delivery, aerodynamic particle control, or propellant compatibility. That lowers manufacturing complexity but also reduces the possibility of device-based differentiation.

Compared with oral antihistamines, montelukast has stronger pediatric granule and chewable-tablet relevance but carries a more serious neuropsychiatric warning. A product strategy should therefore emphasize administration and adherence rather than broad superiority claims.

What licensing and commercial partnership opportunities exist?

Licensing value is most credible in four areas:

• Pediatric taste-masking technology.
• Proprietary ODT or multiparticulate platforms.
• Regional manufacturing and regulatory registrations.
• Contract development and manufacturing for private-label generics.

A platform company could license a taste-masking system to multiple montelukast manufacturers, but freedom-to-operate analysis must account for overlapping excipient and coating patents. A generic manufacturer may prefer an exclusive regional license when the technology secures hospital formulary access or improves pediatric tender performance.

Fixed-dose combinations with antihistamines or other respiratory agents are technically possible but commercially riskier. They require clinical justification, combination-specific labeling, and a clear adherence or treatment advantage. The boxed warning makes unsupported combination positioning particularly difficult.

Key Takeaways

• Montelukast’s core U.S. patent exclusivity has expired, and standard tablets are highly commoditized.
• The best formulation opportunities are pediatric granules, aspartame-free chewables, dye-free products, taste-masked ODTs, and moisture-protected unit-dose packaging.
• Mannitol, microcrystalline cellulose, hydroxypropyl cellulose, croscarmellose sodium, crospovidone, and alternative sweetener systems are central excipient options.
• Excipient substitution alone is unlikely to create strong patent protection.
• Patent value increases when the formulation produces measurable improvements in taste, stability, dissolution, content uniformity, or administration.
• FDA’s 2020 boxed warning limits promotional claims and reduces the value of convenience-only reformulations.
• No biosimilar pathway applies. Competition is through ANDAs, branded generics, authorized generics, and selected 505(b)(2) products.
• Manufacturing reliability, pediatric acceptability, packaging performance, and geographic registration are more important than core-molecule exclusivity.

FAQs

Can montelukast be formulated without aspartame?

Yes. Aspartame can be replaced with sucralose, acesulfame potassium, steviol glycosides, polyols, or combinations of sweeteners. The formulation must be reoptimized for bitterness, aftertaste, tablet strength, and stability.

Is mannitol a suitable excipient for pediatric montelukast?

Yes. Mannitol is suitable for chewable tablets and oral granules because it supports sugar-free positioning and can improve mouthfeel. Excessive polyol exposure may create gastrointestinal tolerability concerns.

Can a new montelukast chewable tablet receive patent protection?

Potentially, but a conventional sweetener or filler substitution is weak patent subject matter. Stronger claims would require a defined taste-masking structure, stability advantage, manufacturing process, or dissolution profile supported by comparative data.

Does montelukast have biosimilar competition?

No. Montelukast is a chemically synthesized small molecule. Competition is through generic drug applications rather than biosimilar applications.

Is montelukast still commercially attractive for generic manufacturers?

Yes, but primarily as a high-volume, low-margin product with opportunities in pediatric supply, private-label manufacturing, regional markets, and differentiated excipient profiles. The commercial case is weaker for another undifferentiated 10 mg tablet.

References

1. U.S. Food and Drug Administration. (2020). FDA requires boxed warning about serious mental health side effects for asthma and allergy drug montelukast. FDA Drug Safety Communication.

2. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

3. Merck & Co., Inc. (2019). Singulair (montelukast sodium) tablets, chewable tablets, and oral granules: Prescribing information.

4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application process for generic drugs. FDA.